Isomorphic Labs, leveraging AI breakthroughs from DeepMind, is on the brink of human clinical trials for cancer drugs. With major pharma partnerships, the future of drug design looks promising!
As Americans gear up for Independence Day celebrations, many businesses will close their doors. Check out our guide to what's open and closed this Fourth of July, including grocery stores, pharmacies, and more!
President Trump leaves the G7 summit early to address the intensifying Israel-Iran conflict. Panic ensues in Tehran as tensions rise. Meanwhile, Purdue Pharma's $7.4 billion opioid settlement stirs debates.
All 50 states and U.S. territories have approved a monumental $7.4 billion settlement with Purdue Pharma for its role in the opioid crisis. The plan aims to hold the Sackler family accountable while providing funds for communities recovering from addiction.
A pharmacy error nearly led to tragedy for a 9-year-old boy when he was mistakenly given a potent opioid instead of his ADHD medication. His family shares their alarming experience and urges caution.
In a surprising turn, Anne Wojcicki's nonprofit, TTAM Research Institute, has acquired 23andMe for $305 million after its bankruptcy. This acquisition addresses concerns about genetic data privacy while aiming to uphold the company's mission.
Anne Wojcicki's nonprofit has won the bid to buy 23andMe, raising critical questions about the future of genetic data privacy. Experts warn that sensitive DNA information could be at risk.
In a groundbreaking move, 27 states and D.C. have filed a lawsuit to prevent 23andMe from selling customer genetic data without consent. This legal battle raises significant privacy concerns for users.
Hims & Hers Health is set to acquire European telehealth platform Zava, aiming to expand its services across Europe. The deal promises to add 1.3 million customers and enhance access to affordable medications in Ireland, France, and Germany.
In a surprising turn of events, Regeneron has announced its acquisition of 23andMe for $256 million following the company's bankruptcy. The pharma giant aims to leverage 23andMe's vast customer data for drug discovery while prioritizing privacy and security.
